CoChat

Incretin-Based Therapies and Diabetic Retinopathy: Real-World Evidence in Older U.S. Adults

Open access
Wang, Tiansheng, Hong, Jin-Liern, Gower, Emily W., Pate, Virginia, Garg, Seema, Buse, John B., Stürmer, Til · 2018 · Diabetes Care
Cited by 52

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: Recent large trials yield conflicting results on the association between incretin-based therapies (IBTs) and diabetic retinopathy (DR). We examined whether IBTs increase DR risk compared with other antihyperglycemics. RESEARCH DESIGN AND METHODS: We implemented an active comparator, new-user cohort design using a nationwide 20% random sample of fee-for-service U.S. Medicare beneficiaries aged 65 years or older with Parts A, B, and D coverage between 2007 and 2015. We identified the following cohorts without prior treatment for retinopathy: dipeptidyl peptidase 4 inhibitors (DPP4i) versus sulfonylureas (SU), DPP4i versus thiazolidinediones (TZD), glucagon-like peptide-1 receptor agonists (GLP1RA) versus long-acting insulin (LAI), and GLP1RA versus TZD. Primary outcome was advanced diabetic retinopathy requiring treatment (ADRRT), defined as a procedure code for retinopathy treatment. Incident diabetic retinopathy (IDR), identified by a diagnosis code, was a secondary outcome. We estimated propensity scores to balance confounders and adjusted hazard ratios (95% CI) using weighted Cox proportional hazards models. RESULTS: We identified 213,652 eligible patients. During a median duration of 0.58 to 0.87 years across comparisons, with a rate from 6.0 to 12.8 per 1,000 person-years, IBTs were not associated with increased ADRRT or IDR risk. The adjusted hazard ratios (95% CI) for ADRRT were 0.91 (0.79–1.04) by comparing DPP4i to SU (n = 39,292 and 87,073); 0.91 (0.75–1.11), DPP4i to TZD (n = 51,410 and 22,231); 0.50 (0.39–0.65), GLP1RA to LAI (n = 9,561 and 82,849); and 0.75 (0.53–1.06), GLP1RA to TZD (n = 10,355 and 27,345). CONCLUSIONS: Our population-based cohort study of older U.S. adults with diabetes suggests that IBTs used for approximately 1 year do not increase the DR risk.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc17-2285

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 26

  1. Gokhale, 2014, Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study, Diabetes Obes Metab, 16, 1247, 10.1111/dom.12379 · DOI · Paper page
  2. Gilbert, 2015, Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy, Lancet, 385, 2107, 10.1016/S0140-6736(14)61402-1 · DOI · Paper page
  3. Gokhale, 2017, No increased risk of cardiovascular events in older adults initiating dipeptidyl peptidase-4 inhibitors vs therapeutic alternatives, Diabetes Obes Metab, 19, 970, 10.1111/dom.12906 · DOI
  4. Holman, 2017, Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes, N Engl J Med, 377, 1228, 10.1056/NEJMoa1612917 · DOI · Paper page
  5. American Diabetes Association, 2017, Pharmacologic approaches to glycemic treatment. Sec. 8. In Standards of Medical Care in Diabetes—2017, Diabetes Care, 40, S64, 10.2337/dc17-S011 · DOI · Paper page
  6. Solomon, 2017, Diabetic retinopathy: a position statement by the American Diabetes Association, Diabetes Care, 40, 412, 10.2337/dc16-2641 · DOI · Paper page
  7. Parikh, 2017, Trends of anti-vascular endothelial growth factor use in ophthalmology among privately insured and Medicare Advantage patients, Ophthalmology, 124, 352, 10.1016/j.ophtha.2016.10.036 · DOI
  8. Varadhan, 2011, GLP-1 agonist treatment: implications for diabetic retinopathy screening, Diabetes Res Clin Pract, 94, e68, 10.1016/j.diabres.2011.08.017 · DOI
  9. Martinell, 2016, Prevalence and risk factors for diabetic retinopathy at diagnosis (DRAD) in patients recently diagnosed with type 2 diabetes (T2D) or latent autoimmune diabetes in the adult (LADA), J Diabetes Complications, 30, 1456, 10.1016/j.jdiacomp.2016.08.009 · DOI
  10. Sato, 2003, Marginal structural models as a tool for standardization, Epidemiology, 14, 680, 10.1097/01.EDE.0000081989.82616.7d · DOI · Paper page
  11. Cole, 2004, Adjusted survival curves with inverse probability weights, Comput Methods Programs Biomed, 75, 45, 10.1016/j.cmpb.2003.10.004 · DOI · Paper page
  12. Rubin, 2004, Multiple Imputation for Nonresponse in Surveys
  13. Silva, 2015, Telemedicine and eye examinations for diabetic retinopathy: a time to maximize real-world outcomes, JAMA Ophthalmol, 133, 525, 10.1001/jamaophthalmol.2015.0333 · DOI
  14. Makri, 2013, Drug-induced macular edema, Drugs, 73, 789, 10.1007/s40265-013-0055-x · DOI
  15. Nencini, 2008, Retinopathy induced by drugs and herbal medicines, Eur Rev Med Pharmacol Sci, 12, 293
  16. Stürmer, 2007, Adjustments for unmeasured confounders in pharmacoepidemiologic database studies using external information, Med Care, 45, S158, 10.1097/MLR.0b013e318070c045 · DOI
  17. Stürmer, 2013, Cancer incidence among those initiating insulin therapy with glargine versus human NPH insulin, Diabetes Care, 36, 3517, 10.2337/dc13-0263 · DOI
  18. Wahl, 2016, Erratum to: Assessment of predictive performance in incomplete data by combining internal validation and multiple imputation, BMC Med Res Methodol, 16, 170, 10.1186/s12874-016-0271-7 · DOI
  19. Sterne, 2009, Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls, BMJ, 338, b2393, 10.1136/bmj.b2393 · DOI · Paper page
  20. Simó, 2017, GLP-1R as a target for the treatment of diabetic retinopathy: friend or foe?, Diabetes, 66, 1453, 10.2337/db16-1364 · DOI · Paper page
  21. Hernández, 2017, Topical administration of DPP-IV inhibitors prevents retinal neurodegeneration in experimental diabetes, Diabetologia, 60, 2285, 10.1007/s00125-017-4388-y · DOI
  22. The Kroc Collaborative Study Group, 1988, Diabetic retinopathy after two years of intensified insulin treatment. Follow-up of the Kroc Collaborative Study, JAMA, 260, 37, 10.1001/jama.1988.03410010045032 · DOI · Paper page
  23. Lauritzen, 1985, Two-year experience with continuous subcutaneous insulin infusion in relation to retinopathy and neuropathy, Diabetes, 34, 74, 10.2337/diab.34.3.S74 · DOI · Paper page
  24. Idris, 2012, Association between thiazolidinedione treatment and risk of macular edema among patients with type 2 diabetes, Arch Intern Med, 172, 1005, 10.1001/archinternmed.2012.1938 · DOI · Paper page
  25. Gower, 2018, Lack of longitudinal association between thiazolidinediones and incidence and progression of diabetic eye disease: the ACCORD Eye study, Am J Ophthalmol, 187, 138, 10.1016/j.ajo.2017.12.007 · DOI
  26. Chubak, 2012, Tradeoffs between accuracy measures for electronic health care data algorithms, J Clin Epidemiol, 65, 343, 10.1016/j.jclinepi.2011.09.002 · DOI · Paper page

Cited by

Metadata

Authors
Wang, T., Hong, J.-L., Gower, E. W., Pate, V., Garg, S., Buse, J. B., & Stürmer, T.
Venue
Diabetes Care
Published
2018-07-16
Volume
41
Issue
9
Pages
1998-2009
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2883137353
Cited by
52
References
10
FWCI
4.26
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.